InnovaMatrix® AC

Placental Extracellular Matrix

InnovaMatrix® Advanced Care is the first-ever placenta-derived medical device cleared by the FDA for wound management.

Why InnovaMatrix® Platform

As the first of its kind, InnovaMatrix® Platform advances the science of the wound management, burn care, and surgical markets by combining the technological advantages of a medical device with the inherent benefits found within the placenta.


  • Medical device quality control regulations and standards
  • Consistency of raw materials
  • Lower cost
  • All of the same placental-derived benefits found in human cells, tissues, and cellular and tissue-based products (HCT/Ps)
  • Ability to create larger sizes
  • Application: no preparation is required, no specific orientation for placement, and the product easily conforms to wound anatomy
  • Room temperature storage

Manufactured with our proprietary TriCleanse Placental Extracellular Matrix (ECM) Process, Convatec Triad Life Sciences, LLC achieves a critical balance between thorough decellularization (cell and cell debris removal) and the preservation of the ECM’s protein structure. The final product – InnovaMatrix® AC – is a thoroughly decellularized bioactive scaffold that allows host cells to infiltrate the affected area, deposit collagen, and easily and quickly remodel the defect. This allows providers and patients to progress well beyond symptom management and instead focus on the tissue’s own capacity to repair itself while addressing any underlying issues with healing.

After an extensive review of Triad’s stringent testing, product characterization, proprietary processing technology, and quality control systems, the FDA cleared InnovaMatrix® AC as the first-ever placental-derived medical device.

A Critical Balance

Effective decellularization removes cells and cellular debris while maintaining the structural proteins of the ECM1.

A Delicate Balance graphic

The Importance of Decellularization

The presence of cells and cellular debris in an ECM can cause an inflammatory response by the host wound site to remove such debris through a type 1 macrophage response of phagocytosis. The TriCleanse Process makes effective decellularization of the ECM possible and provides a cleaner scaffold in which the host wound site can respond upon placement via deposits of collagen.1,3

Materials for Advanced Care

While the benefits of placental-derived allografts are well documented,2 human-derived grafts can be variable due to the unique medical histories and social behaviors of each donor. Knowing this challenge, Triad selected a porcine source because it can be controlled for age, diet, health, and activity level, thereby greatly reducing the variability of the raw material used to manufacture InnovaMatrix® AC. Along with this consistent and highly controlled source material, InnovaMatrix® AC is manufactured under the strict guidelines of Triad’s medical device quality system to ensure our customers are provided with reliable and reproducible ECM products.


  1. Gilpin, A., & Yang, Y. (2017). Decellularization Strategies for Regenerative Medicine: From Processing Techniques to Applications. Biomed Res Int, 2017, 9831534.
  2. Fairbairn, N. G., Randolph, M. A., & Redmond, R. W. (2014). The clinical applications of human amnion in plastic surgery. Journal of Plastic, Reconstructive & Aesthetic Surgery, 67(5), 662-675.
  3. Keane, T.J., Londono, R., Turner, N.J., & Badylak, S. F. (2012). Consequences of ineffective decellularization of biologic scaffolds on the host response. Biomaterials, 33(6), 1771-1781. doi:10.1016/j/biomatierlas.2011.10.054